Avacta and LG Chem agree multi-target R&D collaboration

10 December 2018

London-listed Avacta Group (AIM: AVCT) has agreed a multi-target collaboration with LG Chem Life Sciences, the life sciences division of the South Korean LG Group.

Under the terms of the deal, LG Chem gains the exclusive global rights to develop and commercialize multiple therapeutics stemming from Avacta’s Affimer technology. Financial details were not disclosed.

The candidates are in the fields of inflammatory disorders, and oncology. The firms will work together to progress these candidates through to drug candidate selection and LG Chem will be responsible for preclinical and clinical development and worldwide marketing of any resulting products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK